Literature DB >> 3263035

Abnormal myocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenylpentadecanoic acid and tomographic imaging.

V Ugolini1, C L Hansen, P V Kulkarni, D E Jansen, M S Akers, J R Corbett.   

Abstract

The radioidinated synthetic fatty acid iodine-123 phenylpentadecanoic acid (IPPA) has proven useful in the identification of regional abnormalities of cardiac metabolism in patients with myocardial ischemia. The present study was performed to test the hypothesis that the myocardial distribution and turnover of fatty acids, assessed noninvasively with IPPA, are altered in patients with cardiomyopathy. Nine normal volunteers and 19 patients with dilated cardiomyopathy of various etiologies underwent cardiac imaging with single-photon emission computed tomography (SPECT) after intravenous injection of IPPA. Apical short-axis and basal short-axis sections were reconstructed and quantitatively analyzed for relative IPPA activity distribution and washout. Patients with congestive cardiomyopathy demonstrated significantly greater heterogeneity of IPPA uptake than normal subjects (maximal percent variation of activity 27 +/- 11 vs 18 +/- 4, p less than 0.01). They also demonstrated a more rapid percent washout rate than control subjects (24 +/- 8 vs 17 +/- 6 for the apical short-axis section, p less than 0.05; 26 +/- 7 vs 18 +/- 5 for the basal short-axis section, p less than 0.01). These abnormalities of fatty acid distribution and turnover were independent of the etiology of the cardiomyopathy. The degree of heterogeneity of IPPA uptake was significantly related to the patients' New York Heart Association functional class (r = 0.64, p less than 0.01). Thus, compared with normal myocardium, the myocardium of patients with congestive cardiomyopathy demonstrates a more heterogeneous distribution of fatty acid uptake, which parallels the clinical severity of the disease. Furthermore, patients with congestive cardiomyopathy demonstrate a more rapid myocardial clearance of the labeled fatty acid, as assessed with SPECT imaging.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263035     DOI: 10.1016/0002-9149(88)90894-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Abstention from alcohol in dilated cardiomyopathy: complete regression of the clinical disease but persistence of myocardial perfusion defects on exercise thallium-201 tomography.

Authors:  Y Juillière; C Gillet; N Danchin; A Thouvenin; G Karcher; F Paille; A Bertrand; D Barrucand; F Cherrier
Journal:  Eur J Nucl Med       Date:  1990

2.  The right stuff.

Authors:  H W Strauss
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

Review 3.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

4.  Clinical use of nuclear cardiology in the assessment of heart failure.

Authors:  Shinro Matsuo; Kenichi Nakajima; Seigo Kinuya
Journal:  World J Cardiol       Date:  2010-10-26

5.  Combined thallium-201 and dynamic iodine-123 iodophenylpentadecanoic acid single-photon emission computed tomography in patients after acute myocardial infarction with effective reperfusion.

Authors:  W S Richter; S Beckmann; M Cordes; T Schuppenhauer; M Schartl; D L Munz
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

6.  Myocardial defect detected by 123I-BMIPP scintigraphy and left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy.

Authors:  Y Hashimoto; H Yamabe; M Yokoyama
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

7.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

8.  Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy.

Authors:  Y Takeishi; J Chiba; S Abe; I Tonooka; A Komatani; H Tomoike
Journal:  Eur J Nucl Med       Date:  1992

9.  Myocardial scintigraphy with iodine-123 phenylpentadecanoic acid and thallium-201 in patients with coronary artery disease: a comparative dual-isotope study.

Authors:  R Zimmermann; B Rauch; M Kapp; B Bubeck; F J Neumann; F Seitz; P Stokstad; G Mall; H Tillmanns; W Kübler
Journal:  Eur J Nucl Med       Date:  1992

10.  Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course.

Authors:  Y Yazaki; M Isobe; W Takahashi; H Kitabayashi; O Nishiyama; M Sekiguchi; T Takemura
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.